Tamper resistant dosage forms

Patent metadata

Field	Value
Publication number	US-9763886-B2
Application number	US-201715413505-A
Country	US
Kind code	B2
Filing date	Jan 24, 2017
Priority date	Aug 25, 2006
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

First claim

The invention claimed is:

1. A method of producing a plurality of solid oral extended release pharmaceutical dosage forms comprising the steps of:
mixing at least one active agent, at least one high molecular weight polyethylene oxide (PEO) having an approximate molecular weight of from 1 million to 15 million, to provide a PEO composition;
compressing the PEO composition to provide a plurality of shaped matrix compositions;
curing the shaped matrix compositions by exposure to heated air at a curing temperature that is at least the softening temperature of the high molecular weight PEO for a curing time of at least about 5 minutes, to provide a plurality of cured matrix compositions;
cooling the cured matrix compositions;
optionally combining any of the matrix compositions with at least one additive, before or after curing; and
optionally providing the cured matrix compositions with at least one film coating, after curing and cooling; wherein
(a) the molecular weight of each PEO is based on rheological measurements;
(b) the high molecular weight PEO comprises at least about 30% (by weight) of each dosage form;
(c) the total weight of each dosage form is calculated by excluding the combined weight of said film coatings; and
(d) each cured matrix composition comprises a solid oral pharmaceutical dosage form that provides an extended release of at least one active agent.

2. A method according to claim 1 , wherein the curing temperature is at least about 60° C. and the curing time is at least about 10 minutes.

3. A method according to claim 2 , wherein the high molecular weight PEO has an approximate molecular weight of from 1 million to 8 million.

4. A method according to claim 3 , wherein the high molecular weight PEO comprises at least about 45% (by weight) of each dosage form.

5. A method according to claim 3 , wherein the high molecular weight PEO comprises at least about 50% (by weight) of each dosage form.

6. A method according to claim 5 , wherein the curing temperature is from about 65° C. to about 90° C. and the curing time is from about 10 minutes to about 10 hours.

7. A method according to claim 3 , wherein the high molecular weight PEO comprises at least about 60% (by weight) of each dosage form.

8. A method according to claim 3 , wherein the high molecular weight PEO comprises at least about 80% (by weight) of each dosage form.

9. A method according to claim 2 , wherein the high molecular weight PEO has a molecular weight that is selected from at least one of 1 million, 2million, 4 million, 5 million, 7 million, and 8 million.

10. A method according to claim 9 , wherein the curing temperature is from about 65° C. to about 90° C. and the curing time is from about 10 minutes to about 10 hours.

11. A method of producing a plurality of solid oral extended release pharmaceutical tablets comprising the steps of:
mixing at least one active agent comprising an opioid or a pharmaceutically acceptable salt thereof, and at least one high molecular weight polyethylene oxide (PEO) having an approximate molecular weight of from 1 million to 8 million, to provide a PEO composition;
compressing the PEO composition to provide a plurality of tablet shaped matrix compositions;
curing the shaped matrix compositions by exposure to heated air at a curing temperature that is at least about 60° C. for a curing time of at least about 10 minutes, to provide a plurality of cured matrix compositions;
cooling the cured matrix compositions;
combining the matrix compositions with at least one additive, before or after curing; and
optionally providing the cured matrix compositions with at least one film coating, after curing and cooling; wherein
(a) the molecular weight of each PEO is based on rheological measurements;
(b) the high molecular weight PEO comprises at least about 50% (by weight) of each dosage form;
(c) the total weight of each tablet is calculated by excluding the combined weight of said film coating; and
(d) each cured matrix composition comprises a solid oral pharmaceutical tablet that provides an extended release of at least one active agent.

12. A method according to claim 11 , wherein at least one additive or film coating is present, and comprises at least one of butylated hydroxytoluene (BHT), magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, micro crystalline cellulose, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, triacetin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and copolymers comprising methyl methacrylate.

13. A method according to claim 11 , wherein
at least one additive comprises an anti-tacking agent;
the curing and cooling steps are conducted in a convection curing device comprising a bed of free flowing tablets;
the heated air comprises inlet air and exhaust air entering and leaving the convection curing device;
the curing temperature does not exceed about 90° C.;
the curing time does not exceed about 10 hours;
the cooling temperature is below about 50° C.; and
each of the curing temperature and the cooling temperature is one of (a) the temperature of the inlet air, (b) the temperature of the exhaust air; and (c) the temperature inside the convection curing device.

14. A method according to claim 13 , wherein the combining step comprises at least one of blending, compressing, layering, spraying, and coating.

15. A method according to claim 13 , wherein each of the curing temperature and the cooling temperature is the temperature of the exhaust air.

16. A method according to claim 15 , wherein the high molecular weight PEO has an approximate molecular weight that is selected from at least one of 1 million, 2 million, 4 million, 5 million, 7 million, and 8 million.

17. A method according to claim 15 , wherein the high molecular weight PEO has an approximate molecular weight of 4 million.

18. A method according to claim 15 , wherein the high molecular weight PEO has an approximate molecular weight of 7 million.

19. A method according to claim 15 , wherein the high molecular weight PEO has an approximate molecular weight that is selected from 1 million, 2million, 4 million, and 7 million.

20. A method according to claim 19 , wherein at least one film coating is present.

21. A method according to claim 19 , wherein the high molecular weight PEO comprises at least about 65% (by weight) of each tablet.

22. A method according to claim 19 , wherein the high molecular weight PEO comprises at least about 79% (by weight) of each tablet.

23. A method according to claim 19 , wherein at least one additive or film coating is present, and comprises at least one of butylated hydroxytoluene (BHT), magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, micro crystalline cellulose, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, triacetin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and copolymers comprising methyl methacrylate.

24. A method according to claim 19 , wherein the anti-tacking agent comprises magnesium stearate.

25. A method according to claim 19 , wherein at least one additive comprises an antioxidant.

26. A method according to claim 25 , wherein the antioxidant comprises butylated

Assignees

• Purdue Pharma Lp
• Purdue Pharmaceuticals LP

Inventors

• Mckenna William H
• Mannion Richard O
• O'Donnell Edward P
• Huang Haiyong H

Classifications

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P29/02

  without antiinflammatory effect · CPC title

• A61K9/2086 Primary

  Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28) · CPC title